Skip to content
10-Q

Quarterly Report

Yew Bio-Pharm Group, Inc.

0001213900-20-016138

← back to feed
Filed
Jun 29, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · Jun 26, 2020 51.7M sh
Short Term Debt Q1 2020 · Mar 31, 2020 $8.14M
Short Term Debt Q1 2020 · Dec 31, 2019 $8.54M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $377.65K
Cash And Equivalents Q1 2020 · Dec 31, 2019 $742.29K
Cash And Equivalents Q1 2020 · Mar 31, 2019 $221.73K
Cash And Equivalents Q1 2020 · Dec 31, 2018 $521.67K
Current Liabilities Q1 2020 · Mar 31, 2020 $9.8M
Current Liabilities Q1 2020 · Dec 31, 2019 $10.48M
Total Liabilities Q1 2020 · Mar 31, 2020 $12.08M
Total Liabilities Q1 2020 · Dec 31, 2019 $12.81M
Current Assets Q1 2020 · Mar 31, 2020 $11.6M
Current Assets Q1 2020 · Dec 31, 2019 $11.67M
Total Assets Q1 2020 · Mar 31, 2020 $52.81M
Total Assets Q1 2020 · Dec 31, 2019 $54.21M
Shares Diluted Q1 2020 · Mar 31, 2019 52.12M sh
Capex Q1 2020 · Mar 31, 2019 $632
Operating Cash Flow Q1 2020 · Mar 31, 2019 $1.77M
Stockholders Equity Q1 2020 · Mar 31, 2019 $42.49M
Stockholders Equity Q1 2020 · Dec 31, 2018 $41.09M
Eps Diluted Q1 2020 · Mar 31, 2019 $0.01
Eps Basic Q1 2020 · Mar 31, 2019 $0.01
Sga Expense Q1 2020 · Mar 31, 2019 $294.97K
Net Income Q1 2020 · Mar 31, 2019 $377.04K
Operating Income Q1 2020 · Mar 31, 2019 $545.27K
Gross Profit Q1 2020 · Mar 31, 2019 $1.16M
Cost Of Revenue Q1 2020 · Mar 31, 2019 $10.36M